IXI IXICO plc
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About IXICO (LON: IXI)
›
IXICO (LON: IXI) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 79 employees.
The shares were at 13.00 GBp on 19 November 2026, up 20.9% over 52 weeks. Its 52-week range is 6.260 GBp to 17.00 GBp: the price is 23.5% below the high and 107.7% above the low.
Its market capitalisation is 28.47M GBP.
IXICO reports return on equity of -14.1%, an operating margin of -39.4% and revenue up 23.1% year over year.
It holds more cash than debt, a net cash position of 1.12M GBP. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 26.00 GBp is 100.0% above the current price.